IntroductionVenetoclax plus hypomethylating agents (VEN+HMA) has shown remarkable efficacy in elderly and unfit AML patients. However, prospective studies comparing VEN+HMA to standard intensive chemotherapy in young and fit AML patients are lacking. We conducted a...
BackgroundVenetoclax (ven) with azacitidine (aza) is the standard of care for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy (IC) due to age or comorbidities. However, fit patients with poor-risk disease biology may not benefit...
Disease relapse is the leading cause of death in patients undergoing RIC allo-HCT, affecting up to 40% of patients. TSC-100 and TSC-1001 are donor-derived T-cell receptor engineered T-cells designed to selectively eliminate residual disease cells post-HCT by targeting...
Despite recent advancements in the treatment of acute myeloid leukemia (AML) the outcome in the relapsed and refractory setting remains poor (Thol, Dohner et al. 2024). While the use of T cell engaging bispecific antibodies (TCE) targeting B cell lineage antigens such...
Background. Despite treatment advances, patients with advanced acute myeloid leukemia (AML) have a poor prognosis. While Chimeric Antigen Receptor (CAR) T and NK-cells (CAR-T/NK) targeting CD123 and CD33 have been extensively evaluated in AML, major challenges include...
Recent Comments